Lucid Diagnostics, Inc.
7
1
1
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
25%
1 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype
Role: collaborator
Clinical Utility of a Non Endoscopic Device EsoCheck and Biomarker EsoGuard as Alternative to Endoscopy for Screening for Barrett's Esophagus in At Risk Population
Role: lead
CLUE: CLinical Utility Study of EsoGuard
Role: lead
Lucid Registry Study
Role: lead
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC
Role: lead
Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE
Role: lead
Pilot Study of Esocheck in Eosinophilic Esophagitis
Role: collaborator
All 7 trials loaded